Literature DB >> 2160321

Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.

S C Yang1, L B Owen-Schaub, J A Roth, E A Grimm.   

Abstract

Synergistic and cooperative effects in vitro of OKT3, interleukin 2 (IL-2), and tumor necrosis factor alpha (TNF) as stimuli in generating effectors with lymphokine-activated killer activity were studied. Activation of human peripheral blood mononuclear cells with OKT3 (10 ng/ml) for 48 h, followed by culture in low concentrations of IL-2 (10 units/ml) and TNF (250 units/ml) resulted in higher cell recovery (50- to 3300-fold) compared to the number of cells in the initial culture and enhanced lytic activity against both Raji and fresh lung tumor targets (mean 100-fold) by day 30 compared to those expanded with higher concentrations of IL-2 (100 units/ml) alone. Immunofluorescence analysis of peripheral blood mononuclear cells initiated with OKT3 and expanded with IL-2 plus TNF revealed a selective increase in CD8+ cells and a decrease in CD4+ by day 28; the opposite effect was observed when cells were incubated with 100 units/ml of IL-2 alone, resulting in a greater proportion of CD4+ cells. Almost all cells were CD3+. Studies of cytokine receptor expression indicated that OKT3 plus IL-2 plus TNF caused an earlier up-regulation of the IL-2 receptor beta chain (Tac) and higher TNF receptor expression by day 6 compared to 100 units/ml IL-2 alone. Significant TNF levels (greater than 17 units/ml) were measured in culture supernatants from peripheral blood mononuclear cells initiated with OKT3 alone. Collectively, our data demonstrate that induction of lymphokine-activated killer activity with OKT3, followed by culture in low concentrations of IL-2 plus TNF is an alternative to the use of high-dose IL-2 alone and suggest that this combination may provide potential advantages in long-term generation of cytolytic cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2160321

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor beta inhibition of lymphokine-activated killer cell generation.

Authors:  J Koberda; E A Grimm; R P Moser
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

2.  High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells.

Authors:  J Koberda; L Bergmann; P S Mitrou; D Hoelzer
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  Characterization of tumor-necrosis-factor-gene-transduced tumor-infiltrating lymphocytes from ascitic fluid of cancer patients: analysis of cytolytic activity, growth rate, adhesion molecule expression and cytokine production.

Authors:  Y Itoh; Y Koshita; M Takahashi; N Watanabe; Y Kohgo; Y Niitsu
Journal:  Cancer Immunol Immunother       Date:  1995-02       Impact factor: 6.968

4.  Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cells.

Authors:  Johan C K Tay; Junjian Wang; Zhicheng Du; Yu Yang Ng; Zhendong Li; Yuefang Ren; Chang Zhang; Jianqing Zhu; Xue Hu Xu; Shu Wang
Journal:  Mol Ther Methods Clin Dev       Date:  2021-03-03       Impact factor: 6.698

5.  Augmentation by tumor necrosis factor alpha of the systemic therapeutic effect of lymphokine-activated killer cells in adoptive immunotherapy of murine tumor.

Authors:  K Kato; T Tanabe; T Agatsuma; S Suzuki; H Nitanai; Y Hashimoto
Journal:  Jpn J Cancer Res       Date:  1991-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.